Figure 7.

IgG purified from ECTM- and Δ16ECTM-immune sera decreased cell viability in trastuzumab-resistant BT-474.R BC cells. Cells were incubated for 72 h in the presence of increasing concentrations of control IgG (A) or ECTM-IgG (B) or Δ16ECTM-IgG (C) or trastuzumab (D) and cell viability was determined by MTT assay. The results are expressed as percentage of living cells ± SEM with respect to control (untreated cells). Columns report the means of mean of three separate experiments, wherein each treatment was repeated in 6 wells. One-way ANOVA followed by Dunnett’s post-hoc tests (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 vs. control).